Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 6-7, 2010, Pages 527-532

  Caby, Fabienne ^a,b   Valin, Nadia ^c   Marcelin, Anne Genevieve ^a,b,d   Schneider, Luminata ^a,b   Andrade, Régis ^a,b   Guiguet, Marguerite ^b   Tubiana, Roland ^a,b   Canestri, Ana ^a,b   Valantin, Marc Antoine ^a,b   Peytavin, Gilles ^a   Pacanowski, Jérome ^c   Morand Joubert, Laurence ^a   Calvez, Vincent ^a,b,d   Girard, Pierre Marie ^b,c,d   Katlama, Christine ^a,b,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Université PMC Paris VI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VIRUS RNA; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; OBSERVATIONAL STUDY; PERSISTENT VIRUS INFECTION; VIREMIA; VIRUS INHIBITION; VIRUS RESISTANCE; ANALYSIS OF VARIANCE; ANTIVIRAL RESISTANCE; BLOOD; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; MIDDLE AGED; MUTATION; PREDICTIVE VALUE; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PYRROLIDINONES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 77953263347     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365541003621502     Document Type: Article

References (22)

1. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354
2. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007;21:395-402.
3. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, et al. Week 24 efficacy and safety of TMC114/ ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11-8.
4. Johnson M. Week-48 results of a phase III randomized doubleblind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1 patients. Conference on Retroviruses and Opportunistic Infections (poster presentation). Boston, USA; 2008.
5. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441
6. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125-133
7. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection (oral abstract session). N Engl J Med 2008;359:355-365
8. Yazdanpanah Y. high rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatmentexperienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial. XVII International AIDS Conference (oral abstract session). Mexico; 2008.
9. Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vezinet F, et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV- 1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 2003;8:427-434
10. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000;160:1123-1132
11. Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999;15:1631-1638
12. Casado JL, Perez-Elias MJ, Antela A, Sabido R, Marti-Belda P, Dronda F, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998;12:F131-5.
13. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, et al. Predictors of virological rebound in HIV- 1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002;16:21-29
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. USA guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Washington DC: Department of Health and Human Services; 2009. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. Accessed date: December 1, 2009.
15. Prise en charge médicale des personnes infectées par le VIH. Publisher: flammarion. Recommandations françaises du groupe d'experts sous la direction du Professeur P. YENI. August 22, 2008. Available at: http://www.sante.gouv.fr accessed date: august 19, 2008.
16. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe (2009). Available at: http://www.europeanaidsclinicalsociety. org. Accessed date: november 2009.
17. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;52:1351-1358
18. Fikkert V, Hombrouck A, Van Remoortel B, De Maeyer M, Pannecouque C, De Clercq E, et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004;18:2019-2028
19. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008;10:67-84.
20. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007;12: 563-570
21. Eron J. Switching from stable lopinavir/ritonavir (LPV/r)-based to raltegravir (RAL)-based combination antiretroviral therapy (ART) resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. Conference on Retroviruses and Opportunistic Infections (oral abstract session). Montreal, Canada; 2009.
22. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007;4:e36.